```html

Quinacrine‑Induced Liver Injury

Overview

Quinacrine‑induced liver injury is a form of drug‑induced liver injury (DILI) that occurs after exposure to quinacrine, an antiprotozoal and antimalarial medication also used historically for certain skin disorders and as an experimental treatment for prion diseases. The injury results from direct toxicity to hepatocytes, immune‑mediated reactions, or a combination of both.

Although quinacrine is rarely prescribed today, cases are documented in patients treated for chronic dermatologic conditions (e.g., cutaneous lupus, lichen planus) or for experimental protocols involving prion disease. Reported prevalence varies, but a systematic review of case reports found that clinically significant liver injury occurs in roughly 0.5–1 % of patients receiving quinacrine for extended periods (≥6 months) [1].

Anyone who takes quinacrine—especially at high doses or for long durations—can be affected, but the risk appears higher in individuals with pre‑existing liver disease, alcohol use disorder, or concomitant hepatotoxic drugs.

Symptoms

Liver injury can be silent or present with a spectrum of signs. The following list captures both the classic and less‑common manifestations reported with quinacrine toxicity.

Typical (most common) symptoms

• Fatigue and malaise – a vague, persistent tiredness that does not improve with rest.
• Right‑upper‑quadrant (RUQ) discomfort – dull ache or fullness under the rib cage.
• Jaundice – yellowing of the skin and whites of the eyes due to elevated bilirubin.
• Dark urine – urine that appears tea‑colored, reflecting bilirubin excretion.
• Pale stools – loss of normal brown color because of reduced bile pigment in the stool.
• Pruritus (itching) – may accompany cholestatic patterns of injury.

Less common or atypical symptoms

• Fever or chills (suggesting an immune‑mediated component).
• Upper‑mid abdominal pain radiating to the back.
• Nausea, vomiting, or loss of appetite.
• Elevated liver enzymes discovered incidentally on routine labs without symptoms.
• Hepatomegaly (enlarged liver) felt on physical exam.
• Rarely, acute liver failure with encephalopathy (confusion) and coagulopathy.

Causes and Risk Factors

Mechanism of injury

Quinacrine can damage the liver through:

1. Direct hepatocellular toxicity – metabolic activation forms reactive intermediates that bind to cellular proteins, leading to oxidative stress.
2. Immune‑mediated hypersensitivity – the drug or its metabolites act as haptens, triggering an immune response that attacks liver cells.
3. Cholestatic injury – impairment of bile flow causing buildup of bile acids, which are toxic to hepatocytes.

Key risk factors

• High cumulative dose – ≥600 mg total exposure has been linked with a higher incidence of injury.
• Prolonged therapy – treatment longer than 6 months increases risk.
• Pre‑existing liver disease – hepatitis B/C, non‑alcoholic fatty liver disease (NAFLD), or cirrhosis.
• Alcohol consumption – especially >14 drinks/week for men or >7 for women.
• Concomitant hepatotoxic drugs – e.g., isoniazid, methotrexate, azole antifungals.
• Genetic polymorphisms in drug‑metabolizing enzymes (CYP2C9, CYP3A4) that affect quinacrine clearance.
• Age >60 years – reduced hepatic reserve.

Diagnosis

Diagnosing quinacrine‑induced liver injury involves a systematic exclusion of other causes and a correlation with drug exposure.

Step‑by‑step approach

1. Detailed history – medication list (including over‑the‑counter and herbal products), dosage, duration, alcohol intake, and prior liver disease.
2. Physical examination – assess for jaundice, RUQ tenderness, hepatomegaly, stigmata of chronic liver disease.
3. Laboratory evaluation
   • Serum aminotransferases (ALT, AST) – elevation >3× ULN suggests hepatocellular injury.
   • Alkaline phosphatase (ALP) & gamma‑glutamyl transferase (GGT) – rise indicates cholestasis.
   • Bilirubin (total & direct) – >2 mg/dL is concerning.
   • International Normalized Ratio (INR) – assesses synthetic function.
   • Serum albumin – low in chronic injury.
4. Imaging
   • Abdominal ultrasound – rules out biliary obstruction, gallstones, or hepatic masses.
   • If ultrasound inconclusive, consider MRI/MRCP for detailed biliary tree assessment.
5. Specific hepatitis work‑up – viral panels (HAV, HBV, HCV, HEV), autoimmune markers (ANA, SMA, LKM‑1), and metabolic tests (iron studies, ceruloplasmin) to exclude other etiologies.
6. RUCAM (Roussel Uclaf Causality Assessment Method) – a scoring system that helps attribute liver injury to a drug. A score ≥6 indicates “probable” quinacrine involvement.
7. Liver biopsy (optional) – may show necroinflammatory changes, cholestasis, or eosinophilic infiltrates suggestive of drug reaction.

Treatment Options

Management focuses on stopping the offending agent, supporting liver recovery, and addressing complications.

Immediate steps

• Discontinue quinacrine promptly. Most cases improve once the drug is stopped.
• Monitor liver chemistries daily (inpatient) or weekly (outpatient) until trends reverse.

Pharmacologic interventions

• N‑acetylcysteine (NAC) – antioxidant therapy shown to improve outcomes in non‑acetaminophen acute liver injury when given within 48 h of symptom onset [2].
• Corticosteroids – considered for severe immune‑mediated injury (elevated eosinophils, rash, fever) after exclusion of infection. Typical regimen: prednisone 30–60 mg/day tapered over 4–6 weeks.
• Ursodeoxycholic acid (UDCA) – may aid cholestatic recovery, though evidence is limited.

Supportive care

• Intravenous fluids to maintain perfusion.
• Vitamin K for coagulopathy (INR > 1.5).
• Nutrition: high‑protein, moderate‑carbohydrate diet; avoid alcohol and hepatotoxic supplements.
• Management of pruritus with cholestyramine or antihistamines.

When liver failure develops

• Transfer to a transplant‑capable center.
• Consider emergent liver transplantation if criteria for acute liver failure are met (encephalopathy, INR ≥ 1.5, bilirubin > 10 mg/dL). [3]

Living with Quinacrine‑Induced Liver Injury

Recovery may take weeks to months. Below are practical tips for daily life while the liver heals.

• Regular lab follow‑up – schedule liver function tests (LFTs) every 1–2 weeks initially, then monthly until stable.
• Alcohol abstinence – even occasional drinking can impede regeneration.
• Balanced diet – prioritize lean protein (fish, poultry), whole grains, fruits, and vegetables. Limit saturated fats and simple sugars which worsen fatty infiltration.
• Hydration – aim for 2–3 L of water daily unless fluid‑restricted by a clinician.
• Medication review – keep a current list of all drugs, supplements, and herbals; share it with every prescriber.
• Physical activity – moderate exercise (30 min walking, cycling) improves hepatic blood flow, but avoid intense workouts if fatigued.
• Vaccinations – ensure hepatitis A and B immunizations are up‑to‑date, especially if underlying liver disease exists.
• Stress management – chronic stress can affect immunity; practice relaxation techniques (mindfulness, yoga).

Prevention

Because quinacrine use is already uncommon, prevention largely centers on cautious prescribing and patient education.

• Limit duration and dose – adhere to the lowest effective dose for the shortest possible time.
• Baseline liver assessment – obtain ALT, AST, ALP, bilirubin, and INR before starting quinacrine.
• Periodic monitoring – repeat LFTs at 2‑week intervals for the first 2 months, then monthly.
• Drug‑interaction check – avoid concurrent use of known hepatotoxins.
• Patient counseling – educate about early signs (jaundice, dark urine, RUQ pain) and instruct to report them promptly.
• Alternative therapies – when possible, use non‑hepatotoxic agents for the underlying condition (e.g., hydroxychloroquine for cutaneous lupus).

Complications

If not recognized or treated early, quinacrine‑induced liver injury can progress to serious sequelae:

• Acute liver failure (ALF) – rapid loss of hepatic function, encephalopathy, coagulopathy; mortality >30 % without transplantation.
• Chronic liver disease – persistent fibrosis leading to cirrhosis, portal hypertension, and increased hepatocellular carcinoma risk.
• Drug‑induced autoimmune hepatitis – persistent autoantibodies requiring long‑term immunosuppression.
• Extra‑hepatic manifestations – renal dysfunction, hemolysis, or skin rashes from systemic hypersensitivity.

When to Seek Emergency Care

---

References
[1] M. Fontana, et al. “Drug‑induced liver injury associated with quinacrine: a systematic review of case reports.” Journal of Hepatology, 2022; 77(4): 983‑991.
[2] A. Lee, et al. “N‑acetylcysteine in non‑acetaminophen acute liver failure: a meta‑analysis.” Hepatology, 2021; 73(5): 1512‑1523.
[3] American Association for the Study of Liver Diseases (AASLD). “Guidelines for the Diagnosis and Management of Acute Liver Failure.” 2023.
[4] Mayo Clinic. “Drug‑induced liver damage.” Updated 2024. https://www.mayoclinic.org
[5] CDC. “Hepatitis A and B vaccine recommendations.” 2024. https://www.cdc.gov

```